Overview

ALF-STONE: Alfuzosin in Uretheric Stones

Status:
Terminated
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to assess the effect of Alfuzosin compared with placebo, for 7 days, on the outcome of patients with uretheric stones submitted to Extracorporeal Shock Wave Lithotripsy (ESWL), namely in the percentage of patients without imagiologic evidence of any stone after 72h to 96 hours. This study will also specifically focus on the evaluation of time of stone clearance and of pain reduction (Numeric Rating Scale).
Phase:
Phase 3
Details
Lead Sponsor:
Sanofi
Treatments:
Alfuzosin